Compare Deutsche Bank AG (DB) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Heron Therapeutics Inc — how do they compare? Deutsche Bank AG trades at $36.53 (market cap $68.51B), while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Deutsche Bank AG is far larger — about 830.2× Heron Therapeutics Inc's market cap, and Deutsche Bank AG pays a 3.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DB | HRTX | |
|---|---|---|
Market Cap | $68.51B | $82.52M |
Sector | Financials | Health |
52-Week High | $40.33 | $2.04 |
52-Week Low | $28.37 | $0.39 |
Dividend Yield | 3.26% | — |
Enterprise Value | — | $180.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $35.24, down 1.48% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows attractive valuation metrics with a P/E of 9.79 and P/B of 0.76. Recent quarterly earnings have consistently beaten expectations, and the company announced a $1.00 dividend for H1-26. However, 2024 cash flow was negative $33.10 billion, though it improved to a positive $7.6 billion in 2025.
The outlook is mixed; strong profitability and earnings beats support upside, but regulatory scrutiny and volatile cash flows pose risks. Analyst consensus is cautious with 57.58% hold ratings. The stock's low valuation may appeal to value investors, yet headline risks from recent legal searches require monitoring.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
